Department of Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, New York.
Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York.
Cancer Res. 2022 Apr 1;82(7):1365-1379. doi: 10.1158/0008-5472.CAN-21-1327.
MET exon 14 skipping alteration (METΔ14Ex) is an actionable oncogenic driver that occurs in 2% to 4% of non-small cell lung cancer (NSCLC) cases. The precise role of METΔ14Ex in tumor progression of NSCLC is poorly understood. Using multiple isogenic METΔ14Ex cell models established with CRISPR editing, we demonstrate that METΔ14Ex expression increases receptor kinase activity and downstream signaling by impairing receptor internalization and endocytic degradation, significantly boosting cell scatter, migration, and invasion capacity in vitro as well as metastasis in vivo. RNA sequencing analysis revealed that METΔ14Ex preferentially activates biological processes associated with cell movement, providing novel insights into its unique molecular mechanism of action. Activation of PI3K/Akt/Rac1 signaling and upregulation of multiple matrix metallopeptidases (MMP) by METΔ14Ex induced cytoskeleton remodeling and extracellular matrix disassembly, which are critical functional pathways that facilitate cell invasion and metastasis. Therapeutically, MET inhibitors dramatically repressed METΔ14Ex-mediated tumor growth and metastasis in vivo, indicating potential therapeutic options for METΔ14Ex-altered NSCLC patients. These mechanistic insights into METΔ14Ex-mediated invasion and metastasis provide a deeper understanding of the role of METΔ14Ex in NSCLC.
These findings reveal the mechanistic function of METΔ14Ex alteration in driving metastasis and define novel metastasis-related pathways that could be targeted for more effective treatment of lung cancer with METΔ14Ex alterations.
MET 外显子 14 跳跃改变(METΔ14Ex)是一种可作用的致癌驱动因素,发生在 2%至 4%的非小细胞肺癌(NSCLC)病例中。METΔ14Ex 在 NSCLC 肿瘤进展中的确切作用尚未完全了解。使用 CRISPR 编辑建立的多个同基因 METΔ14Ex 细胞模型,我们证明 METΔ14Ex 表达通过损害受体内化和内吞降解来增加受体激酶活性和下游信号,显著增强体外细胞散射、迁移和侵袭能力以及体内转移。RNA 测序分析表明,METΔ14Ex 优先激活与细胞运动相关的生物学过程,为其独特的作用机制提供了新的见解。METΔ14Ex 激活 PI3K/Akt/Rac1 信号和上调多个基质金属蛋白酶(MMP)诱导细胞骨架重塑和细胞外基质解体,这是促进细胞侵袭和转移的关键功能途径。在治疗上,MET 抑制剂可显著抑制 METΔ14Ex 介导的体内肿瘤生长和转移,表明 METΔ14Ex 改变的 NSCLC 患者有潜在的治疗选择。这些关于 METΔ14Ex 介导的侵袭和转移的机制见解加深了对 METΔ14Ex 在 NSCLC 中的作用的理解。
这些发现揭示了 METΔ14Ex 改变在驱动转移中的机制功能,并定义了新的转移相关途径,这些途径可针对具有 METΔ14Ex 改变的肺癌进行更有效的治疗。